Pharmacy

Your Article Summary

See Latest Articles

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis
Current Medical Research and Opinion, 07/09/09

Sheng M et al. - Assuming median progression-free survival of 8.5 months as shown for bevacizumab, the incremental costs would be estimated at $39188–42080 per patient compared to those treated with sunitinib or sorafenib. Assuming similar efficacies, oral AI therapies may result in cost savings to patients and healthcare payers over IV therapies.

Today in Chemotherapy/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Clinical Cancer Research, 12/01/09

Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 12/01/09

 See all of Chemotherapy/Oncology

Today in Pharmacoeconomics...keeping you current

Receive free subspecialty "5-minute updates" via email

Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
PharmacoEconomics, 11/30/09

Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
PharmacoEconomics, 11/24/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

 See all of Pharmacoeconomics